Archemix Corp., a Cambridge, Mass.-based biopharma company focused on developing aptamer therapeutics, has filed for a $69 million IPO. It plans to trade on the Nasdaq under ticker symbol ARCH, with Banc of America Securities and Bear Stearns serving as co-lead underwriters. Archemix has raised around $132 million in VC funding since 2001, from firms like Atlas Venture (14% pre-IPO stake), Prospect Venture Partners (14%), Highland Capital Parnters (13.3%), SV Life Sciences (11.7%), KGaA (11.4%), Rho Ventures (9.7%) and Care Capital (5.3%). www.archemix.com
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.